Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• Tumor necrosis factor- ⁇ is a cytokine which is released primarily by mononuclear phagocytes in response to a number immunostimulators. It is a key
• TNF ⁇ appears to be involved in bone resorption diseases, including arthritis. When activated, leukocytes will produce bone-resorption, an activity to which the data suggest
• TNF ⁇ contributes. ⁇ Bertolini et al, Nature 319, 516-518 (1986) and Johnson et al,
• TNF ⁇ also has been shown to stimulate bone resorption and inhibit bone formation in vitro .and in vivo through stimulation of osteo- clast formation and activation combined with inhibition of osteoblast function.
• TNF ⁇ may be involved in many bone resorption diseases, including arthritis, the most compelling link with disease is the association between production of TNF ⁇ by tumor or host tissues and malignancy associated hypercalcemia ⁇ Calci.
• increased serum TNF ⁇ levels have been associated with major complication following acute allogenic bone marrow transplants ⁇ Holler et al, Blood, 75(4), 1011-1016 (1990) ⁇ .
• Cerebral malaria is a lethal hyperacute neurological syndrome associated with high blood levels of TNF ⁇ and the most severe complication occurring in malaria patients. Levels of serum TNF ⁇ correlated directly with the severity of disease and the prognosis in patients with acute malaria attacks ⁇ Grau et al, N. Engl. J. Med. 320(24), 1586-1591
• Macrophage-induced angiogenesis is known to be mediated by TNF ⁇ .
• Leibovich et al. ⁇ Nature, 329, 630-632 (1987) ⁇ showed TNF ⁇ induces in vivo capillary blood vessel formation in the rat cornea and the developing chick chorioallantoic membranes at very low doses and suggest TNF ⁇ is a candidate for inducing angiogenesis in inflammation, wound repair, and tumor growth.
• TNF ⁇ production also has been associated with cancerous conditions, particularly induced tumors ⁇ Ching et al, Brit. J. Cancer, (1955) 72, 339-343, and Koch, Progress in Medicinal Chemistry, 22, 166-242 (1985) ⁇ .
• TNF ⁇ also plays a role in the area of chronic pulmonary inflammatory diseases.
• the deposition of silica particles leads to silicosis, a disease of progressive respiratory failure caused by a fibrotic reaction.
• Antibody to TNF ⁇ completely blocked the silica-induced lung fibrosis in mice ⁇ Pignet et al, Nature, 344, 245-247 (1990) ⁇ .
• High levels of TNF ⁇ production have been demonstrated in animal models of silica and asbestos induced fibrosis ⁇ Bissonnette et al, Inflammation 13(3), 329-339 (1989) ⁇ .
• Alveolar macrophages from pulmonary sarcoidosis patients have also
• TNF ⁇ is also implicated in the inflammatory response which follows reperfusion, called reperfusion injury, .and is a major cause of tissue damage after loss of blood flow ⁇ Vedder et al, PNAS 87, 2643-2646 (1990) ⁇ .
• TNF ⁇ also alters the properties of endothelial cells and has various pro-coagulant activities, such as producing an increase in tissue factor pro-coagulant activity and suppression of the anticoagulant protein C pathway as well as down-regulating the expression of thrombomodulin ⁇ Sherry et al, J. Cell Biol 107, 1269-1277 (1988) ⁇ .
• TNF ⁇ has pro-inflammatory activities which together with its early production (during the initial stage of an inflammatory event) make it a likely mediator of tissue injury in several important disorders including but not limited to, myocardial infarction, stroke and circulatory shock.
• adhesion molecules such as intercellular adhesion molecule (ICAM) or endothelial leukocyte adhesion molecule (ELAM) on endothelial cells ⁇ M_ ⁇ mo et al, Am. J. Path. 135(1), 121-132 (1989) ⁇ .
• TNF ⁇ blockage with monoclonal anti-TNF ⁇ antibodies has been shown to be beneficial in rheumatoid arthritis ⁇ Elliot et al, Int. J. Pharmac. 1995 17(2), 141-145 ⁇ .
• TNF ⁇ is a potent activator of retrovirus replication including activation of HIV-1. ⁇ Duh et al, Proc. Nat. Acad. Sci. 86, 5974-5978 (1989);
• Retrovirus 191-197 (1992) ⁇ . AIDS results from the infection of T lymphocytes with
• HIV 3- Human Immunodeficiency Virus
• HIV-1 HIV-1
• HIV-2 HIV-2
• HIV-3 HIV-3
• T-cell mediated immunity is impaired and infected individuals manifest severe opportunistic infections and/or unusual neoplasms.
• HIV entry into the T lymphocyte requires T lym- phocyte activation.
• Other viruses, such as HIV-1, HIV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV gene expression and/or HIV replication.
• Cytokines are implicated in acti- vated T-cell mediated HIV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with cytokine activity such as by prevention or inhibition of cytokine production, notably TNF ⁇ , in an HIV-infected individual assists in limiting the maintenance of T lymphocyte caused by HIV infection.
• Monocytes, macrophages, and related cells have been implicated in maintenance of the HIV infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells. ⁇ Rosenberg et al, The Immunopathogenesis of HIV Infection,
• Cytokines such as TNF ⁇
• TNF ⁇ have been shown to activate HIV replication in monocytes and/or macrophages ⁇ Poli et al, Proc. Natl. Acad. Sci., 87, 782-784 (1990) ⁇ , therefore, prevention or inhibition of cytokine production or activity aids in limiting HIV progression for T cells. Additional studies have identified
• TNF ⁇ as a common factor in the activation of HIV in vitro and has provided a clear mechanism of action via a nuclear regulatory protein found in the cytoplasm of cells
• TNF ⁇ in AIDS associated cachexia is suggested by elevated serum TNF ⁇ and high levels of spontaneous TNF ⁇ production in peripheral blood monocytes from patients ⁇ Wright et al, J. Immunol. 141(1), 99-104 (1988) ⁇ .
• TNF ⁇ has been implicated in various roles with other viral infections, such as the cytomegalia virus (CMV), influenza virus, adenovirus, and the herpes family of viruses for similar reasons as those noted.
• CMV cytomegalia virus
• influenza virus influenza virus
• adenovirus adenovirus
• herpes family of viruses for similar reasons as those noted.
• NFKB nuclear factor KB
• the nuclear factor KB is a pleiotropic transcriptional activator (Lenardo, et al, Cell 1989, 58, 227-29).
• NFKB has been implicated as a transcriptional activator in a variety of disease and inflammatory states and is thought to regulate cytokine levels including but not limited to TNF ⁇ and also to be an activator of HIV transcription (Dbaibo, et al, J. Biol. Chem. 1993, 17762-66; Duh et al, Proc. Natl. Acad. Sci. 1989, 86, 5974-78; Bachelerie et al, Nature 1991, 350, 709-12; Boswas et al, J.
• NFKB binding can regulate transcription of cytokine gene(s) and through this modulation and other mechanisms be useful in the inhibition of a multitude of disease states.
• the compounds described herein can inhibit the action of NFKB in the nucleus and thus are useful in the treatment of a variety of diseases including but not limited to rheumatoid arthritis, rheumatoid spondylitis, osteo- arthritis, other arthritic conditions, septic shock, septis, endotoxic shock, graft versus host
• TNF ⁇ and NFKB levels are influenced by a reciprocal feedback loop.
• the compounds of the present invention affect the levels of both TNF ⁇ and NFKB.
• cAMP cAMP
• inflammatory conditions and diseases including asthma, inflammation, and other conditions
• cAMP inflammatory mediators
• Phosphodiesterases control the level of cAMP through hydrolysis and inhibitors of phosphodiesterases have been shown to increase cAMP levels.
• TNF ⁇ levels and/or increasing cAMP levels thus constitutes a valuable therapeutic strategy for the treatment of many inflammatory, infectious, immunological or malignant diseases.
• diseases include but are not restricted to septic shock, sepsis, endotoxic shock, hemodynamic shock and sepsis syndrome, post ischemic reperfusion injury, malaria, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, opportunistic infections in AIDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic condi- tions, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythrematosis, ENL in leprosy, radiation damage, and hyperoxic alveolar injury.
• the present invention is based on the discovery that certain classes of non- polypeptide compounds more fully described herein decrease the levels of TNF ⁇ , increase cAMP levels, and inhibit inflammatory cytokines.
• the present invention thus relates to 1-oxo- and l,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines substituted in the 4-position of the isoindoline ring and optionally further substituted in the 3 -position of the 2,6-dioxopiperidine ring , the method of reducing levels of tumor necrosis factor ⁇ and other inflammatory cytokines in a mammal through the administration of such derivatives, and pharmaceutical compositions containing such derivatives.
• the invention pertains to
• Y is oxygen or H 2 ,
• a first of R 1 and R 2 is halo, aikyl, alkoxy, alkylamino, dialkylamino, cyano, or carbamoyl,
• the second of R 1 and R 2 independently of the first, is hydrogen, halo, aikyl, alkoxy, alkylamino, dialkylamino, cyano, or carbamoyl, and
• R 3 is hydrogen, aikyl, or benzyl, and (b) the acid addition salts of said 2-(2,6-dioxopiperidin-3-yl)-isoindolines which contain a nitrogen atom capable of being protonated.
• aikyl denotes a univalent saturated branched or straight hydrocarbon chain containing from 1 to 4 carbon atoms.
• Representative of such aikyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
• Alkoxy refers to an aikyl group bound to the remainder of the molecule through an ethereal oxygen atom.
• Representative of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy.
• Halo includes bromo, chloro, fluoro, and iodo.
• the compounds of Formula I are used, under the supervision of qualified professionals, to inhibit the undesirable effects of TNF ⁇ and other inflammatory cytokines including the interleukins IL-1, IL-6, and IL-12.
• the compounds can be administered orally, rectally, or parenterally, alone or in combination with other therapeutic agents including antibiotics, steroids, chemotherapeutic agents, etc., to a mammal in need of treatment; e.g., in the treatment of cancers, rheumatoid arthritis, inflammatory bowel disease, muscular dystrophy, Crohn's disease, etc..
• the compounds of the present invention also can be used topically in the treatment or prophylaxis of disease states mediated or exacerbated by excessive TNF ⁇ production, respectively, such as viral infections, such as those caused by the herpes viruses, or viral conjunctivitis, psoriasis, atopic dermatitis, etc.
• TNF ⁇ mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples include feline immunodeficiency virus, equine infectious anaemia virus, caprine arthritis virus, visna virus, and maedi virus, as well as other lenti viruses.
• the compounds of Formula I are readily prepared through a number of routes.
• an anhydride or lactone is allowed to react with a 3-amino-2,6-dioxo- piperidine:
• each of R 1 , R 2 , R 3 , and Y are as defined above.
• the 3-amino-2,6-dioxopiperidine can be obtained from the corresponding glutamic acid anhydride through conventional amidation or from the cyclization of appropriate glutamine derivatives..
• R 4 is CHO or CH 2 Br in the presence of an acid acceptor such as dimethylaminopyridine or triethylamine.
• disubstituted benzoate intermediates are known or can be obtained though conventional processes.
• 9- acid is brominated with N-bromosuccinimide under the influence of light to yield the lower aikyl 2-(bromomethyl)-3,6-disubstitutedbenzoate.
• racemates of these isomers and the individual isomers themselves, as well as diastereomers when a second chiral center is present, are within the scope of the present invention.
• the racemates can be used as such or can be separated into their individual isomers mechanically as by chromatography using a chiral absorbent.
• the individual isomers can be prepared in chiral form or separated chemically from a mixture by forming salts with a chiral acid or base, such as the individual enantiomers of 10-cam- phorsulfonic acid, camphoric acid, ⁇ -bromocamphoric acid, methoxyacetic acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, and the like, and then freeing one or both of the resolved bases, optionally repeating the process, so as obtain either or both substantially free of the other; i.e., in a form having an optical purity of>95%.
• a chiral acid or base such as the individual enantiomers of 10-cam- phorsulfonic acid, camphoric acid, ⁇ -bromocamphoric acid, methoxyacetic acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid,
• the present invention also pertains to the physiologically acceptable non-toxic acid addition salts of the compound of Formula I which contain a group capable of being pro- tonated; e.g., amino.
• Such salts include those derived from organic and inorganic acids such as, without limitation, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulphonic acid, acetic acid, tartaric acid, lactic acid, succinic acid,
• Particularly preferred compounds include l,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4- methylisoindoline, 1 ,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-ethylisoindoline, 1 ,3-dioxo-2- (2,6-dioxo-3-methylpiperidin-3-yl)-4-methylisoindoline, 1 ,3-dioxo-2-(2,6- dioxoopiperidin-3-yl)-4,7-dimethylisoindoline, l-oxo-2-(2,6-dioxo-3-methylpiperidin-3- yl)-4-ethylisoindoline, l-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-methylisoindoline, 1 -ox
• l,3-dioxo-2-(2,6-dioxopiperidin- 3-yl)-4-methylisoindoline 1 ,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4,7-dimethylisoindoline, l-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline, and 1 oxo-2-(2,6-dioxopiperidin- 3-yl)-4,7-dimethylisoindoline are particularly preferred.
• Oral dosage forms include tablets, capsules, dragees, and similar shaped, compressed pharmaceutical forms containing from 1 to 100 mg of drug per unit dosage.
• Isotonic sal- ine solutions containing from 20 to 100 mg/mL can be used for parenteral administration which includes intramuscular, intrathecal, intravenous and intra-arterial routes of administration. Rectal administration can be effected through the use of suppositories formulated from conventional carriers such as cocoa butter.
• compositions thus comprise one or more compounds of Formulas I associated with at least one pharmaceutically acceptable carrier, diluent or excipient.
• active ingredients are usually mixed with or diluted by
• compositions can be in the form of tablets, pills, powders, elixirs, suspensions, emulsions, solutions, syrups, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
• excipients examples include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidinone, cellulose, water, syrup, and methyl cellulose
• the formulations can additionally include lubricating agents such as talc, magnesium stearate and mineral oil, wetting agents, emulsifying and suspending agents, preserving agents such as methyl- and propylhydroxybenzoates, sweetening agents or flavoring agents.
• compositions preferably are formulated in unit dosage form, meaning physically discrete units suitable as a unitary dosage, or a predetermined fraction of a unitary dose to be administered in a single or multiple dosage regimen to human subjects and other mam- mals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with a suitable pharmaceutical excipient.
• the compositions can be formulated so as to provide an immediate, sustained or delayed release of active ingredient after administration to the patient by employing procedures well known in the art.
• Enzyme-linked immunosorbent assays for TNF ⁇ can be performed in a conventional manner.
• PBMC is isolated from normal donors by Ficoll-Hypaque density centrifugation. Cells are cultured in RPMI supplemented with 10% AB+ serum, 2mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin. Drugs are dissolved in dimethylsulfoxide (Sigma Chemical) and further dilutions are done in supplemented RPMI. The final dimethylsulfoxide concentration in the presence or absence of drug in the PBMC suspensions is 0.25 wt %. Drugs are assayed at half-log dilutions starting at 50 mg/mL.
• PBMC 13- Drugs are added to PBMC (10 6 cells/mL) in 96 wells plates one hour before the addition of LPS.
• PBMC (10 6 cells/mL) in the presence or absence of drug are stimulated by treatment with 1 mg/mL of LPS from Salmonella minnesota R595 (List Biological Labs, Campbell, CA). Cells are then incubated at 37° C for 18-20 hours. Supernatants are harvested and assayed immediately for TNF ⁇ levels or kept frozen at -70°C (for not more than 4 days) until assayed.
• the concentration of TNF ⁇ in the supernatant is determined by human TNF ⁇ ELISA kits (ENDOGEN, Boston, MA) according to the manufacturer's directions.
• 2-(2,6-Dioxopiperid-3-yl)-4,7-dimethylisoindoline-l,3-dione was prepared by the procedure of Example 1 from 3,6-dimethylphthalic anhydride (220 mg, 1.25 mmol), 3- aminopiperidine-2,6-dione hydrogen chloride (204 mg, 1.24 mmol) and sodium acetate (110 mg, 1.34 mmol) in acetic acid (10 mL).
• 2-(2,6-Dioxo(3-piperidyl))-4-ethylisoindoline-l,3-dione was prepared by the procedure of Example 1 from 3-ethylphthalic anhydride (0.860 g, 4.89 mmol), 3- aminopiperidine-2,6-dione hydrogen chloride (0.803 g, 4.88 mmol) and sodium acetate (0.420 g, 5.12 mmol) in acetic acid (10 mL).
• 4-Dimethylamino-2-(2,6-dioxo(3-piperidyl))isoindoline-l,3-dione was prepared by the procedure of Example 1 from 3-dimethylaminophthalic anhydride (1.34 g, 7.0 mmol), 3-aminopiperidine-2,6-dione hydrogen chloride (1.15 g, 7.0 mmol) and sodium acetate (0.60 g, 7.3 mmol) in acetic acid (20 mL).
• 2-(2,6-Dioxo(3-piperidyl))-4-chloroisoindoline-l,3-dione was prepared by the procedure of Example 1 from 3-chlorophthalic anhydride (0.40 g, 2.2 mmol), 3- aminopiperidine-2,6-dione hydrogen chloride (0.36 g, 2.2 mmol) and sodium acetate (0.19 g, 2.4 mmol) in acetic acid (10 mL).
• Tablets each containing 50 mg of l-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methyl- isoindoline, can be prepared in the following manner:
• the solid ingredients are first forced through a sieve of 0.6 mm mesh width.
• the active ingredient, lactose, talc, magnesium stearate and half of the starch then are mixed.
• the other half of the starch is suspended in 40 mL of water and this suspension is added to a boiling solution of the polyethylene glycol in 100 mL of water.
• the resulting paste is added to the pulverulent substances and the mixture is granulated, if necessary with the addition of water.
• the granulate is dried overnight at 35°C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 6 mm diameter which are concave on both sides.
• Gelatin dry-filled capsules each containing 100 mg of l,3-dioxo-2-(2,6-dioxo- piperidin-3-yl)-4-methylisoindoline, can be prepared in the following manner:
• composition for 1000 capsules: l,3-dioxo-2-(2,6-dioxo- piperidin-3 -yl)-4-methyl- isoindoline 100.0 g microcrystalline cellulose 30.0 g sodium lauryl sulfate 2.0 g
• the sodium lauryl sulfate is sieved into the l,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4- methylisoindoline through a sieve of 0.2 mm mesh width and the two components are intimately mixed for 10 minutes.
• the microcrystalline cellulose is then added through a sieve of 0.9 mm mesh width and the whole is again intimately mixed for 10 minutes.
• the magnesium stearate is added through a sieve of 0.8 mm width and, after mixing for a further 3 minutes, the mixture is introduced in portions of 140 mg each into size 0 (elongated) gelatin dry-fill capsules.
• injection or infusion solution can be prepared, for example, in the following manner: l,3-dioxo-2-(2,6-dioxopiperidin-

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Rheumatology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Virology (AREA)
• Molecular Biology (AREA)
• Pain & Pain Management (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Transplantation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Indole Compounds (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Publications (1)

Family

ID=22142431

Family Applications (1)

Country Status (22)

Cited By (32)

Families Citing this family (116)

Citations (6)

Family Cites Families (16)

• 1999
  • 1999-03-16 TR TR2001/01502T patent/TR200101502T2/xx unknown
  • 1999-03-16 US US09/270,411 patent/US20010006973A1/en not_active Abandoned
  • 1999-03-16 KR KR1020007010218A patent/KR100712573B1/ko not_active Expired - Fee Related
  • 1999-03-16 EP EP99911393A patent/EP1064277B1/en not_active Expired - Lifetime
  • 1999-03-16 CN CNB998036641A patent/CN100390163C/zh not_active Expired - Fee Related
  • 1999-03-16 ES ES99911393T patent/ES2243052T3/es not_active Expired - Lifetime
  • 1999-03-16 DK DK99911393T patent/DK1064277T3/da active
  • 1999-03-16 TR TR2000/02681T patent/TR200002681T2/xx unknown
  • 1999-03-16 CA CA2321920A patent/CA2321920C/en not_active Expired - Fee Related
  • 1999-03-16 JP JP2000536709A patent/JP4695259B2/ja not_active Expired - Fee Related
  • 1999-03-16 PT PT99911393T patent/PT1064277E/pt unknown
  • 1999-03-16 KR KR1020077007093A patent/KR20070040423A/ko not_active Ceased
  • 1999-03-16 AT AT99911393T patent/ATE297911T1/de active
  • 1999-03-16 EP EP03012168A patent/EP1357120A1/en not_active Withdrawn
  • 1999-03-16 TR TR2001/01501T patent/TR200101501T2/xx unknown
  • 1999-03-16 WO PCT/US1999/005562 patent/WO1999047512A1/en not_active Ceased
  • 1999-03-16 HU HU0102113A patent/HUP0102113A3/hu unknown
  • 1999-03-16 AU AU30042/99A patent/AU745884B2/en not_active Ceased
  • 1999-03-16 CZ CZ20003356A patent/CZ299253B6/cs not_active IP Right Cessation
  • 1999-03-16 TR TR2001/01500T patent/TR200101500T2/xx unknown
  • 1999-03-16 DE DE69925819T patent/DE69925819T2/de not_active Expired - Lifetime
  • 1999-03-16 TR TR2001/01504T patent/TR200101504T2/xx unknown
  • 1999-03-16 KR KR1020067006763A patent/KR20060036124A/ko not_active Ceased
  • 1999-03-16 TR TR2001/01503T patent/TR200101503T2/xx unknown
  • 1999-03-16 BR BR9908811-8A patent/BR9908811A/pt not_active Application Discontinuation
  • 1999-03-16 NZ NZ506432A patent/NZ506432A/en not_active IP Right Cessation
  • 1999-03-16 SK SK1364-2000A patent/SK13642000A3/sk unknown
  • 1999-03-16 RU RU2000123762/04A patent/RU2200159C2/ru not_active IP Right Cessation
  • 1999-03-16 TR TR2001/01505T patent/TR200101505T2/xx unknown
• 2000
  • 2000-08-21 NO NO20004175A patent/NO20004175L/no not_active Application Discontinuation
  • 2000-08-23 FI FI20001864A patent/FI121272B/fi not_active IP Right Cessation
  • 2000-09-06 US US09/655,571 patent/US6403613B1/en not_active Expired - Lifetime
• 2002
  • 2002-05-13 US US10/144,560 patent/US20030028028A1/en not_active Abandoned
• 2005
  • 2005-09-28 US US11/236,740 patent/US7820697B2/en not_active Expired - Fee Related
• 2007
  • 2007-07-13 US US11/827,802 patent/US20080287496A1/en not_active Abandoned
• 2010
  • 2010-10-22 JP JP2010237215A patent/JP2011042674A/ja not_active Withdrawn

Patent Citations (7)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events